Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Dillard

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Immunology, Immunotherapy : CII|November 29, 2019
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapyNadia Mensali, Marit Renée Myhre, Pierre Dillard, et al.
Nano Letters|July 11, 2015
Size-Tunable Organic Nanodot Arrays: A Versatile Platform for Manipulating and Imaging CellsFuwei Pi, Pierre Dillard, Ranime Alameddine, et al.
BMC Biotechnology|June 4, 2020
Colorectal cysts as a validating tool for CAR therapyPierre Dillard, Maren Lie, Elizabeth Baken, et al.
The Journal of Biological Chemistry|November 25, 2020
Combinatorial CAR design improves target restrictionHakan Köksal, Pierre Dillard, Asta Juzeniene, et al.
Oncoimmunology|February 7, 2019
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunityNadia Mensali, Amalie Grenov, Niladri Bhusan Pati, et al.
Ebiomedicine|January 23, 2019
NK cells specifically TCR-dressed to kill cancer cellsNadia Mensali, Pierre Dillard, Michael Hebeisen, et al.
NPJ Breast Cancer|April 18, 2019
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapyTheodossis A Theodossiou, Muhammad Ali, Mantas Grigalavicius, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 19, 2020
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer ImmunotherapyPierre Dillard, Hakan Köksal, Solrun Melkorka Maggadottir, et al.
Journal of Hematology & Oncology|February 21, 2018
Artesunate shows potent anti-tumor activity in B-cell lymphomaThea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, et al.
Blood Advances|April 14, 2019
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphomaHakan Köksal, Pierre Dillard, Sarah E Josefsson, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|November 29, 2019
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapyNadia Mensali, Marit Renée Myhre, Pierre Dillard, et al.
Nano Letters|July 11, 2015
Size-Tunable Organic Nanodot Arrays: A Versatile Platform for Manipulating and Imaging CellsFuwei Pi, Pierre Dillard, Ranime Alameddine, et al.
BMC Biotechnology|June 4, 2020
Colorectal cysts as a validating tool for CAR therapyPierre Dillard, Maren Lie, Elizabeth Baken, et al.
The Journal of Biological Chemistry|November 25, 2020
Combinatorial CAR design improves target restrictionHakan Köksal, Pierre Dillard, Asta Juzeniene, et al.
Oncoimmunology|February 7, 2019
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunityNadia Mensali, Amalie Grenov, Niladri Bhusan Pati, et al.
Ebiomedicine|January 23, 2019
NK cells specifically TCR-dressed to kill cancer cellsNadia Mensali, Pierre Dillard, Michael Hebeisen, et al.
NPJ Breast Cancer|April 18, 2019
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapyTheodossis A Theodossiou, Muhammad Ali, Mantas Grigalavicius, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 19, 2020
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer ImmunotherapyPierre Dillard, Hakan Köksal, Solrun Melkorka Maggadottir, et al.
Journal of Hematology & Oncology|February 21, 2018
Artesunate shows potent anti-tumor activity in B-cell lymphomaThea Kristin Våtsveen, Marit Renée Myhre, Chloé Beate Steen, et al.
Blood Advances|April 14, 2019
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphomaHakan Köksal, Pierre Dillard, Sarah E Josefsson, et al.
Pageof 3